• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A phase II study of brentuximab vedotin in patients with relapsed or refractory Epstein-Barr virus-positive and CD30-positive lymphomas.

作者信息

Kim Miso, Lee Jeong-Ok, Koh Jiwon, Kim Tae Min, Lee Ji Yun, Jeon Yoon Kyung, Keam Bhumsuk, Kim Dong-Wan, Lee Jong Seok, Heo Dae Seog

机构信息

Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea; Seoul National University Cancer Research Institute, Seoul.

Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam.

出版信息

Haematologica. 2021 Aug 1;106(8):2277-2280. doi: 10.3324/haematol.2021.278301.

DOI:10.3324/haematol.2021.278301
PMID:33792222
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8327727/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7cce/8327727/73085cf22c91/1062277.fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7cce/8327727/c69deb850050/1062277.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7cce/8327727/73085cf22c91/1062277.fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7cce/8327727/c69deb850050/1062277.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7cce/8327727/73085cf22c91/1062277.fig2.jpg

相似文献

1
A phase II study of brentuximab vedotin in patients with relapsed or refractory Epstein-Barr virus-positive and CD30-positive lymphomas.一项关于brentuximab vedotin治疗复发或难治性爱泼斯坦-巴尔病毒阳性和CD30阳性淋巴瘤患者的II期研究。
Haematologica. 2021 Aug 1;106(8):2277-2280. doi: 10.3324/haematol.2021.278301.
2
Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression.在一项复发/难治性弥漫性大 B 细胞淋巴瘤（DLBCL）的 2 期研究中，贝林妥欧单抗显示出了客观应答，且 CD30 表达存在差异。
Blood. 2015 Feb 26;125(9):1394-402. doi: 10.1182/blood-2014-09-598763. Epub 2015 Jan 8.
3
Brentuximab Vedotin-Driven Microtubule Disruption Results in Endoplasmic Reticulum Stress Leading to Immunogenic Cell Death and Antitumor Immunity.本妥昔单抗维迪辛导致微管解聚，引发内质网应激，导致免疫原性细胞死亡和抗肿瘤免疫。
Mol Cancer Ther. 2024 Jan 3;23(1):68-83. doi: 10.1158/1535-7163.MCT-23-0118.
4
Clinical Implications of CD30 Expression in Aggressive B-Cell Lymphomas.CD30表达在侵袭性B细胞淋巴瘤中的临床意义
Clin Lymphoma Myeloma Leuk. 2016 Aug;16(8):429-33. doi: 10.1016/j.clml.2016.04.011. Epub 2016 May 10.
5
CD30 targeting with brentuximab vedotin: a novel therapeutic approach to primary effusion lymphoma.采用 Brentuximab vedotin 靶向 CD30：原发性渗出性淋巴瘤的一种新治疗方法。
Blood. 2013 Aug 15;122(7):1233-42. doi: 10.1182/blood-2013-01-481713. Epub 2013 Jul 9.
6
Brentuximab vedotin.本妥昔单抗维迪西妥单抗
Blood. 2014 Nov 20;124(22):3197-200. doi: 10.1182/blood-2014-06-537514. Epub 2014 Oct 7.
7
Brentuximab vedotin in the treatment of relapsed/refractory CD30+ peripheral T-cell lymphoma: A FIL phase 2 study.本妥昔单抗治疗复发/难治性CD30+外周T细胞淋巴瘤：一项FIL 2期研究。
Hematol Oncol. 2022 Apr;40(2):307-309. doi: 10.1002/hon.2963. Epub 2022 Jan 19.
8
Epstein-Barr virus-positive diffuse large B-cell lymphoma after frontline brentuximab vedotin treatment of classical Hodgkin lymphoma.一线使用本妥昔单抗治疗经典型霍奇金淋巴瘤后发生的爱泼斯坦-巴尔病毒阳性弥漫性大B细胞淋巴瘤
Ann Hematol. 2022 May;101(5):1149-1152. doi: 10.1007/s00277-021-04709-3. Epub 2021 Nov 10.
9
Brentuximab vedotin for relapsed or refractory CD30+ hematologic malignancies: the German Hodgkin Study Group experience.本妥昔单抗维迪昔单抗治疗复发或难治性 CD30+血液系统恶性肿瘤：德国 Hodgkin 研究组的经验。
Blood. 2012 Aug 16;120(7):1470-2. doi: 10.1182/blood-2012-05-430918. Epub 2012 Jul 11.
10
Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacy.苯达莫司汀-维莫非尼治疗60岁及以上复发或难治性CD30阳性淋巴瘤患者：安全性和疗效的回顾性评估
Leuk Lymphoma. 2014 Oct;55(10):2328-34. doi: 10.3109/10428194.2013.876496. Epub 2014 Feb 24.

引用本文的文献

1
Viral oncogenesis in cancer: from mechanisms to therapeutics.癌症中的病毒致癌作用：从机制到治疗
Signal Transduct Target Ther. 2025 May 12;10(1):151. doi: 10.1038/s41392-025-02197-9.
2
The 'Oma's of the Gammas-Cancerogenesis by γ-Herpesviruses.γ疱疹病毒引发的γ细胞癌变——“祖母”因素
Viruses. 2024 Dec 17;16(12):1928. doi: 10.3390/v16121928.
3
Role of rapidly evolving immunotherapy in chronic active Epstein-Barr virus disease.快速发展的免疫疗法在慢性活动性EB病毒病中的作用

本文引用的文献

1
A20 and RBX1 Regulate Brentuximab Vedotin Sensitivity in Hodgkin Lymphoma Models.A20 和 RBX1 调节霍奇金淋巴瘤模型中 Brentuximab Vedotin 的敏感性。
Clin Cancer Res. 2020 Aug 1;26(15):4093-4106. doi: 10.1158/1078-0432.CCR-19-4137. Epub 2020 Apr 16.
2
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.贝林妥欧单抗联合化疗治疗 CD30 阳性外周 T 细胞淋巴瘤（ECHELON-2）：一项全球性、双盲、随机、3 期临床试验。
Lancet. 2019 Jan 19;393(10168):229-240. doi: 10.1016/S0140-6736(18)32984-2. Epub 2018 Dec 4.
3
Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.
Front Immunol. 2024 Dec 3;15:1451977. doi: 10.3389/fimmu.2024.1451977. eCollection 2024.
4
PD-1 inhibitors plus chemotherapy for refractory EBV-positive DLBCL: a retrospective analysis.PD-1抑制剂联合化疗治疗难治性EBV阳性弥漫性大B细胞淋巴瘤：一项回顾性分析
Blood Res. 2024 Oct 30;59(1):36. doi: 10.1007/s44313-024-00042-6.
5
EBV Reactivation and Disease in Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients and Its Impact on HSCT Outcomes.异基因造血干细胞移植（HSCT）受者中 EBV 的再激活与疾病及其对 HSCT 结局的影响。
Viruses. 2024 Aug 14;16(8):1294. doi: 10.3390/v16081294.
6
Challenges in overcoming advanced-stage or relapsed refractory extranodal NK/T-cell lymphoma: meta-analysis of individual patient data.克服晚期或复发难治性结外NK/T细胞淋巴瘤的挑战：个体患者数据的荟萃分析
Front Oncol. 2024 Jul 31;14:1362367. doi: 10.3389/fonc.2024.1362367. eCollection 2024.
7
Novel Targets and Advanced Therapies in Diffuse Large B Cell Lymphomas.弥漫性大B细胞淋巴瘤的新型靶点与先进疗法
Cancers (Basel). 2024 Jun 17;16(12):2243. doi: 10.3390/cancers16122243.
8
A + AVD for Treatment of Hodgkin Lymphoma Variant of Richter's Transformation.A + AVD方案治疗里氏转化型霍奇金淋巴瘤变异型
Case Rep Hematol. 2024 Feb 24;2024:7612622. doi: 10.1155/2024/7612622. eCollection 2024.
9
Treatment-related adverse events of antibody-drug conjugates in clinical trials: A systematic review and meta-analysis.临床试验中抗体药物偶联物的治疗相关不良事件：一项系统评价和荟萃分析。
Cancer Innov. 2023 Oct 15;2(5):346-375. doi: 10.1002/cai2.97. eCollection 2023 Oct.
10
Advances and challenges of immunotherapies in NK/T cell lymphomas.NK/T细胞淋巴瘤免疫治疗的进展与挑战
iScience. 2023 Oct 12;26(11):108192. doi: 10.1016/j.isci.2023.108192. eCollection 2023 Nov 17.
本妥昔单抗联合化疗治疗Ⅲ期或Ⅳ期霍奇金淋巴瘤
N Engl J Med. 2018 Jan 25;378(4):331-344. doi: 10.1056/NEJMoa1708984. Epub 2017 Dec 10.
4
Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis.用于 CD30+ 皮肤 T 细胞淋巴瘤和淋巴瘤样丘疹病的本妥昔单抗 II 期试验结果。
J Clin Oncol. 2015 Nov 10;33(32):3759-65. doi: 10.1200/JCO.2014.60.3787. Epub 2015 Aug 10.
5
Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project.一项关于苯达莫司汀在不同CD30表达水平的蕈样肉芽肿和塞扎里综合征中应用的II期研究者发起研究：一项多机构合作项目。
J Clin Oncol. 2015 Nov 10;33(32):3750-8. doi: 10.1200/JCO.2014.60.3969. Epub 2015 Jul 20.
6
Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression.在一项复发/难治性弥漫性大 B 细胞淋巴瘤（DLBCL）的 2 期研究中，贝林妥欧单抗显示出了客观应答，且 CD30 表达存在差异。
Blood. 2015 Feb 26;125(9):1394-402. doi: 10.1182/blood-2014-09-598763. Epub 2015 Jan 8.
7
Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin.单药 Brentuximab vedotin 治疗复发 T 细胞淋巴瘤的客观缓解。
Blood. 2014 May 15;123(20):3095-100. doi: 10.1182/blood-2013-12-542142. Epub 2014 Mar 20.
8
Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.本妥昔单抗维迪昔（SGN-35）治疗复发或难治性系统性间变大细胞淋巴瘤患者的Ⅱ期研究结果。
J Clin Oncol. 2012 Jun 20;30(18):2190-6. doi: 10.1200/JCO.2011.38.0402. Epub 2012 May 21.
9
Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.一项评估 Brentuximab vedotin 治疗复发或难治性霍奇金淋巴瘤患者的关键性 II 期研究结果。
J Clin Oncol. 2012 Jun 20;30(18):2183-9. doi: 10.1200/JCO.2011.38.0410. Epub 2012 Mar 26.
10
Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer.蕈样肉芽肿和塞扎里综合征的临床终点和反应标准：国际皮肤淋巴瘤学会、美国皮肤淋巴瘤联盟以及欧洲癌症研究与治疗组织皮肤淋巴瘤工作组的共识声明。
J Clin Oncol. 2011 Jun 20;29(18):2598-607. doi: 10.1200/JCO.2010.32.0630. Epub 2011 May 16.